Please login to the form below

Not currently logged in
Email:
Password:

cardiovascular diseases

This page shows the latest cardiovascular diseases news and features for those working in and with pharma, biotech and healthcare.

AZ makes gene therapy move with 4DMT alliance

AZ makes gene therapy move with 4DMT alliance

It also has a long-running collaboration with Moderna seeking messenger RNA drugs for the treatment of cardiovascular, metabolic and renal diseases as well as selected targets in oncology, and is ... Last year, AZ also paid 25m upfront in a research deal

Latest news

More from news
Approximately 5 fully matching, plus 88 partially matching documents found.

Latest Intelligence

  • Finding the patient voice Finding the patient voice

    rheumatoid arthritis, oncology, psychiatry, cardiovascular diseases, rare diseases etc.

  • Deal Watch December 2016 Deal Watch December 2016

    1, 850. Bicycle (UK). AstraZeneca (UK). Licence collaboration. Bicycle platform: small molecules with antibody specificity for targets in respiratory, cardiovascular and metabolic diseases. ... 320. Evotec (Germany). Celgene (US). Discovery collaboration.

  • A healthy challenge A healthy challenge

    Vytenis told PME he is “ very concerned” about the rising burden of chronic non-communicable diseases, such as cardiovascular diseases, cancer and type 2 diabetes. “ ... The risk of developing these diseases is very much increased due to some of

  • Opening up innovation Opening up innovation

    For GlaxoSmithKline its pharma open innovation efforts began with diseases of the developing world, such as malaria - where it offered researchers free access to a 'virtual library' of tens of thousands ... With over 1, 000 potential products being

  • Cost containment and the German market Cost containment and the German market

    Apart from growing revenues from innovative drugs, the sales volumes of medicine for highly prevalent and chronic diseases like cardiovascular indications are expected to increase due to the demographic development. ... Biopharmaceuticals have become

More from intelligence
Approximately 0 fully matching, plus 16 partially matching documents found.

Latest appointments

  • MyoKardia appoints COO and medical affairs VP MyoKardia appoints COO and medical affairs VP

    Prior to this, Dr Lee was therapeutic area head for cardiovascular, metabolic, respiratory and infectious disease programmes at Genentech. ... Meanwhile, Dr Tripuraneni (pictured left) brings over 10 years of medical affairs expertise in a variety of

  • Cardio3 BioSciences appoints Warren Sherman chief medical officer Cardio3 BioSciences appoints Warren Sherman chief medical officer

    therapy and other treatments for cardiovascular diseases.”. ... for the further development of Cardio3 BioSciences' future projects in regenerative therapies and cardiovascular diseases.”.

  • Pfizer appoints diabetes expert Morris Birnbaum Pfizer appoints diabetes expert Morris Birnbaum

    Pfizer appoints diabetes expert Morris Birnbaum. He takes up post as chief scientific officer for cardiovascular and metabolic diseases. ... Pfizer has appointed prominent academic Dr Morris Birnbaum as chief scientific officer for its research into

  • INC Research appoints Dr Martin Sullivan INC Research appoints Dr Martin Sullivan

    INC Research has appointed Dr Martin Sullivan as its new executive director for cardiovascular medicine. ... Sally Osmond, general manager of cardiovascular and endocrinology clinical development at INC Research, said: "The prevalence of cardiovascular

More from appointments
Approximately 0 fully matching, plus 4 partially matching documents found.

Latest from PMHub

More from PMHub
Approximately 0 fully matching, plus 2 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Clark Health Communications

Clark Health Communications (CHC) is an independent, award-winning health and medical communications agency. Our collaboration with experts and advocates enhances...

Latest intelligence

Developing advocacy in the pharmaceutical industry.
The importance of advocacy programmes...
GDPR and events. What does the pharma industry need to know?
Many people in the pharma industry still aren’t following the rules set out by the GDPR when it comes to running events and attending tradeshows. But with eye-watering fines for...
Digital trends in B2B sales - how far behind is Pharma?
The modern approach to B2B sales is data-driven, and enabled by digital tools....

Infographics